RA'ANANA, Israel, Dec. 11,
2023 /PRNewswire/ -- Inspira Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company"
or "Inspira"), a pioneer in life support technology with a
vision to supersede traditional mechanical ventilators, is pleased
to announce the appointment of Dr. Dan Gorfil to its medical
advisory board.
Dr. Gorfil is a distinguished specialist in cardiac surgery and
intensive care medicine. Dr. Gorfil is both the head of the
Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal
Membrane Oxygenation program at the Department of Cardiothoracic
Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to
significantly contribute to the deployment of the
INSPIRA™ ART100. U.S. Food and Drug Administration (FDA)
approval is expected in the first half of 2024.
"My commitment to life support innovation led me to Inspira
Technologies," stated Dr. Gorfil. "I believe that the
Company's innovative technology will revolutionize critical care
treatment. I am thrilled to be a part of this transformative
journey."
Dagi Ben-Noon, CEO of Inspira Technologies, commented,
"Dr. Gorfil's appointment represents a strategic step towards
accelerating our technology's time-to-market. I believe that his
deep expertise and extensive network within the life support sector
are valuable to both patients and our investors.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is leading the way in transforming
life-support care. Its innovative solutions are paving the way for
direct blood oxygenation, bypassing the lungs, and potentially
reducing the need for traditional mechanical ventilation. Beyond
this, the Company is committed to advancing blood circulation
technology and incorporating AI-driven monitoring systems. These
advancements are part of its strategy to offer more
patient-focused, data-informed care. The integration of these
technologies signifies the potential to enhance patient outcomes
and streamline hospital operations, marking a new era in
respiratory care.
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements under U.S. Federal securities laws. These
forward-looking statements and their implications are based only on
the current expectations of the management of the Company. They are
subject to several factors and uncertainties that could cause
results to differ materially from those described in the
forward-looking statements. For example, the Company uses
forward-looking statements when it discusses the Company's vision
to supersede traditional mechanical ventilators, that the Company
expects Dr Gorfil's expertise to significantly contribute to the
deployment of the INSPIRA Art 1000, that FDA approval for the
INSPIRA Art 1000 is expected in the first half of 2024, that Dr.
Gorfil believes that the Company's innovative technology will
revolutionize critical care treatment, and that the Company
believes that Dr. Gorfil's appointment represents a strategic step
towards accelerating the Company's technology's time-to-market.
Except as otherwise required by law, the Company undertakes no
obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or the occurrence of unanticipated events. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the
Company's annual report on Form 20-F for the fiscal year ended
December 31, 2022, filed with the
SEC, which is available on the SEC's website, www.sec.gov.
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2023 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/in-preparation-for-fda-clearance-and-device-deployment-inspira-has-appointed-dr-dan-gorfil-to-medical-advisory-board-302011430.html
SOURCE Inspira Technologies